Post-Vysis Bishop Sees Hope at Cepheid for Real-time Diagnostics | GenomeWeb

John Bishop had the option to stay at Vysis after it was purchased by Abbott Laboratories for about $355 million. “But of course once you’ve successfully spun a company out and taken it public and run it in the market, you’re still not going to be functioning as a CEO [at a subsidiary],” says Bishop, former Vysis CEO and president. He considered several alternatives, but the role of CEO at Cepheid was too appealing to pass up. “What Cepheid offered was something where I could make an immediate contribution.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.